Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Feb 22:6:4.
doi: 10.21037/sci.2019.02.01. eCollection 2019.

Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?

Romualdo Barroso-Sousa  1 , Geoffrey I Shapiro  2 , Sara M Tolaney  3
Affiliations
Editorial

Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?

Romualdo Barroso-Sousa et al. Stem Cell Investig. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: R Barroso-Sousa has served as an advisor/consultant to Eli Lilly and has received honoraria from Roche for participation in Speakers Bureau. GI Shapiro receives research funding from Eli Lilly, Merck KGaA-EMD Serono, Sierra Oncology, Merck, Pfizer and Array Biopharma and has served on advisory boards for Eli Lilly, Merck KGaA-EMD Serono, Sierra Oncology, Pfizer, Astex, Almac, Roche, Bicycle Therapeutics, Fusion Pharmaceuticals, G1Therapeutics, Ipsen, Cybrex Therapeutics, Daiichi-Sankyo and Angiex. SM Tolaney receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odenate, and Nektar. SM Tolaney has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Tesaro, and Nanostring.

Comment on

  • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Tutt A, et al. Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713086 Free PMC article. Clinical Trial.

References

    1. Miles DW, Dieras V, Cortes J, et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013;24:2773-80. 10.1093/annonc/mdt276 - DOI - PubMed
    1. Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol 2018;29:1763-70. 10.1093/annonc/mdy201 - DOI - PMC - PubMed
    1. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018;379:2108-21. 10.1056/NEJMoa1809615 - DOI - PubMed
    1. Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90. 10.1038/nrclinonc.2016.66 - DOI - PMC - PubMed
    1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. 10.1073/pnas.191367098 - DOI - PMC - PubMed